Juq-063 High Quality -

(If you have institutional access, the DOI link above will take you straight to the publisher’s page.)

| Phase | Trial ID | Design | Population | Primary Endpoint | Status (as of Apr 2026) | |-------|----------|--------|------------|------------------|------------------------| | | NCT05873201 | Open‑label, dose escalation (3 + 3) → RP2D identification | Advanced solid tumors harboring KRAS G12D (PDAC, CRC, NSCLC) | Safety, MTD, PK/PD, ORR (exploratory) | Completed (2025); RP2D = 30 mg QD | | Phase Ib/IIa | NCT05984212 | Cohort expansion + pembrolizumab combo (PD‑1 blockade) | KRAS G12D‑mutant PDAC, previously treated | ORR, DCR, PFS (12‑wk) | Ongoing (enrollment 70 % complete) | | Phase IIb | NCT06000123 | Randomized (1:1) JUQ‑063 + standard gemcitabine/nab‑paclitaxel vs. standard chemo alone | Treatment‑naïve KRAS G12D PDAC | PFS, OS, safety | Initiated Q3 2025 | | Phase III (Planned) | NCT06123456 | Global, double‑blind, JUQ‑063 + chemo ± immunotherapy vs. chemo + immunotherapy | Metastatic KRAS G12D PDAC | OS (primary), PFS, QoL | Protocol development 2026, IND filing Q4 2026 | JUQ-063

| Indicator | Estimate | |-----------|----------| | | ~7,800 new PDAC cases annually with KRAS G12D (≈15 % of 52,000 total PDAC). | | Global KRAS G12D‑positive solid tumors | ~25,000‑30,000 patients/year (PDAC + CRC + NSCLC). | | Projected Peak Sales (2028‑2033) | $2.5 B – $3.2 B (assuming 30 % market capture in PDAC, 20 % in CRC/NSCLC). | | Competitive Landscape | No KRAS G12D‑specific inhibitors; existing treatments are cytotoxic chemotherapy ± immunotherapy. | (If you have institutional access, the DOI link

: Standardized to seamlessly integrate with common industrial power grids (e.g., 24V DC control loops or 110V/220V AC power systems). | | Global KRAS G12D‑positive solid tumors |

Verify structural bolts have not backed out due to ambient vibrations. Insulation Resistance